GLP-1 Receptor Agonists and Cognitive Function: Dissecting the EVOKE Trial Outcomes in Alzheimer's Disease

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

The EVOKE and EVOKE+ Phase 3 trials demonstrated that semaglutide did not significantly slow the clinical progression of early symptomatic Alzheimer's disease, despite prior observational data suggesting a reduced risk of dementia with GLP-1 use and some positive biomarker shifts.

The highly anticipated results from the EVOKE and EVOKE+ Phase 3 clinical trials have provided a critical update on the role of GLP-1 receptor agonists (GLP-1RAs), specifically semaglutide, in the treatment of early symptomatic Alzheimer's disease (AD). Contrary to some earlier observational data and preclinical promise, these large-scale trials concluded that semaglutide did not significantly reduce the clinical progression of AD. This outcome, while disappointing for those hoping for a direct disease-modifying effect, offers crucial insights into the complex interplay between metabolic pathways and neurodegeneration, guiding future research directions.

The Rationale: Why GLP-1RAs for Alzheimer's?

Prior to the EVOKE trials, a compelling body of evidence suggested that GLP-1RAs might offer neuroprotective benefits. GLP-1, an incretin hormone, is known for its roles in glucose homeostasis and appetite regulation. However, GLP-1 receptors are also expressed in the brain, leading to hypotheses about their central nervous system effects. Preclinical studies indicated that GLP-1RAs could reduce neuroinflammation, improve cerebral blood flow, enhance insulin signaling in the brain, and promote neurogenesis. Observational studies further fueled this interest, with one pooled analysis of real-world data from over 1 million patients with type 2 diabetes showing that semaglutide treatment was associated with a 40% to 70% reduced risk of a first-time AD diagnosis compared to other antidiabetic medications [4]. Another study in JAMA Neurology similarly found a lower risk of AD in type 2 diabetes patients on GLP-1RAs [5]. These findings provided a strong mechanistic and epidemiological basis for investigating GLP-1RAs in AD.

EVOKE and EVOKE+: Trial Design and Patient Population

The EVOKE (NCT04777396) and EVOKE+ (NCT04777409) trials were designed as randomized, double-blind, placebo-controlled Phase 3 studies. They enrolled a total of 3808 adults aged 55 to 85 years with mild cognitive impairment or mild dementia due to AD. Participants were randomized to receive either oral semaglutide (titrated up to 14 mg daily) or placebo, in addition to standard of care. The primary endpoint was the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score at 104 weeks. Secondary endpoints included other cognitive and functional assessments, as well as biomarker changes. A key distinction was that EVOKE+ included participants with extensive small blood vessel damage in the brain, while EVOKE excluded them, though this difference ultimately had minimal impact on the overall findings due to low enrollment of such patients in EVOKE+ [3].

The Results: Clinical Efficacy and Biomarker Shifts

Presented at the 2025 Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference, the topline results were unequivocal: semaglutide did not demonstrate superiority over placebo in slowing the clinical progression of AD. The curves for semaglutide and placebo groups on the CDR-SB and other cognitive/functional outcomes were virtually indistinguishable over the three-year trial period [1] [2]. This indicates that semaglutide, at the tested dose and duration, did not provide a significant clinical benefit in patients with established early AD.

Despite the lack of clinical efficacy, the trials did reveal some interesting biomarker shifts. In a subset of participants who underwent cerebrospinal fluid (CSF) analysis, semaglutide treatment was associated with nominally significant reductions (up to 10%) in several AD biomarkers, including p-tau181, p-tau217, np-tau181, and np-tau205. Reductions were also observed in the neuroinflammation marker YKL-40 and neurodegeneration markers total tau and neurogranin [3]. Notably, plasma biomarkers did not show similar shifts, with plasma GFAP and NfL even showing slight increases in some groups. However, plasma high-sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation, decreased by approximately 30% in the semaglutide group, suggesting peripheral anti-inflammatory effects that did not translate to cognitive improvement [3].

Implications for Alzheimer's Prevention and Future Research

The EVOKE trial results underscore the complexity of AD pathogenesis and the challenges of translating promising preclinical and observational data into clinical success. While semaglutide did not halt progression in symptomatic AD, the earlier observational data suggesting a reduced risk of AD diagnosis in type 2 diabetes patients on GLP-1RAs remains intriguing. This raises the question of whether GLP-1RAs might have a role in preventing AD or delaying its onset if initiated much earlier, perhaps in individuals at high risk but without overt cognitive impairment. This 'prevention' hypothesis warrants further investigation, potentially in different patient populations or earlier disease stages.

Furthermore, the biomarker data, particularly the CSF p-tau and neuroinflammation markers, suggest that GLP-1RAs do exert some biological effects in the brain, even if these were insufficient to alter clinical trajectory in the EVOKE population. This points towards the potential for GLP-1RAs as part of future combination therapies. As Howard Fillit, MD, of the Alzheimer\u2019s Drug Discovery Foundation noted, existing anti-amyloid drugs slow decline by around 30%, leaving a significant gap. Therapies targeting other pathways, such as metabolic and inflammatory ones, will be crucial. GLP-1RAs could potentially complement amyloid-targeting agents or other emerging treatments, contributing to a multi-modal approach to AD management.

Conclusion

The EVOKE and EVOKE+ trials, while not demonstrating clinical efficacy for semaglutide in early symptomatic Alzheimer's disease, have significantly advanced our understanding. They highlight the need for continued research into the neurobiological effects of GLP-1RAs, particularly in prevention strategies and as components of combination therapies. The journey to effective Alzheimer's treatments is long, and every trial, regardless of outcome, contributes valuable knowledge to this critical endeavor.

References

[1] Novo Nordisk A/S. Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. News release. November 24, 2025. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916462

[2] Ciccone, I. GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease. NeurologyLive. November 24, 2025. https://www.neurologylive.com/view/glp-1-semaglutide-fails-outperform-placebo-phase-3-evoke-trial-ad

[3] O\u2019Leary, K. GLP-1 receptor agonist fails to halt Alzheimer\u2019s disease. Nature Medicine. March 31, 2026. https://www.nature.com/articles/d41591-026-00018-2

[4] Wang W, Wang Q, Qi X, et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20(12):8661-8672. doi:10.1002/alz.14313.

[5] Tang H, Donahoo WT, DeKosky ST, et al. GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias. JAMA Neurol. Published online April 7, 2025. doi:10.1001/jamaneurol.2025.0353.", "word_count": 890, "reading_time_minutes": 4, "is_published": true, "author": "Adam Maggio", "meta_description": "Explore the EVOKE trials' findings on semaglutide for Alzheimer's disease, revealing no clinical benefit but insights for future GLP-1 research, prevention strategies, and combination therapies."}, {"slug": "semaglutide-parkinsons-disease-spark-neuroprotection", "title": "Semaglutide for Parkinson's Disease: Re-evaluating Dopaminergic Neuroprotection in Light of Recent Trial Outcomes", "category": "glp1", "tags": ["semaglutide", "Parkinson's disease", "neuroprotection", "dopamine", "GLP-1RAs", "clinical trials"], "tldr_summary": "Despite promising preclinical data and early-phase trials, recent Phase 3 trials involving GLP-1 receptor agonists like exenatide have shown no significant clinical benefit in slowing Parkinson's disease progression or improving symptoms. While semaglutide's specific SPARK trial results are pending, the broader class's efficacy in advanced PD remains a subject of ongoing investigation.", "content": "The potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, to offer neuroprotection in Parkinson's disease (PD) has been a significant area of research interest. This enthusiasm stemmed from compelling preclinical evidence suggesting GLP-1RAs could mitigate dopaminergic neurodegeneration, a hallmark of PD. However, recent clinical trial outcomes, particularly with other GLP-1RAs like exenatide, have introduced a more nuanced perspective, highlighting the challenges of translating preclinical success into tangible clinical benefits for PD patients.\n\n## The Neuroprotective Promise of GLP-1RAs in PD\n\nParkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to motor symptoms such as tremor, rigidity, and bradykinesia. Current treatments primarily manage symptoms but do not halt or reverse neurodegeneration. GLP-1RAs, initially developed for type 2 diabetes and obesity, have shown a range of neuroprotective properties in animal models of PD. These include reducing neuroinflammation, improving mitochondrial function, enhancing autophagy, and protecting neurons from oxidative stress and excitotoxicity. Crucially, GLP-1RAs have been observed to restore dopamine levels and inhibit dopaminergic loss in these models, suggesting a direct impact on the disease's core pathology [1] [2].\n\nEarly human studies, particularly with exenatide, further fueled optimism. A Phase 2 trial of exenatide in PD patients demonstrated improvements in motor scores compared to placebo, even after a washout period, hinting at a disease-modifying effect [3]. These results prompted larger, more definitive trials to investigate the neuroprotective potential of GLP-1RAs in PD.\n\n## The SPARK Trial and Broader Clinical Landscape\n\nThe SPARK trial (NCT03659682) is a Phase 2, double-blind, randomized, placebo-controlled study designed to assess the neuroprotective and anti-inflammatory properties of semaglutide in idiopathic Parkinson's disease. While specific detailed results for the SPARK trial with semaglutide are still anticipated or have not yet been widely published in definitive clinical outcomes, the broader landscape of GLP-1RA trials in PD has seen mixed results.\n\nNotably, the Phase 3 Exenatide-PD3 trial, a rigorous 96-week study involving 194 participants, concluded that weekly injections of exenatide did not slow PD progression or improve symptoms. This trial, published in The Lancet, found no significant difference in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores between the exenatide and placebo groups [4] [5]. Furthermore, pre- and post-study CT brain scans revealed no impact on dopamine activity in PD-relevant brain regions. This outcome was a significant disappointment, especially given the promising Phase 2 findings.\n\n## Discrepancies and Future Directions\n\nThe divergence between preclinical findings, early-phase clinical hints, and definitive Phase 3 trial results underscores several critical considerations:\n\n Disease Stage: Many preclinical studies are conducted in early disease models, while human trials often involve patients with established PD. It is possible that GLP-1RAs exert neuroprotective effects primarily in very early stages or even pre-symptomatic phases, where neuronal damage is less extensive.\n Blood-Brain Barrier Penetration: While some GLP-1RAs, like lixisenatide, appear to cross the blood-brain barrier more effectively than others, the extent and functional significance of this penetration for different GLP-1RAs in human PD brains remain areas of active research [6].\n Mechanism of Action: The exact neuroprotective mechanisms of GLP-1RAs in humans with PD may differ from those observed in animal models. The complexity of PD pathology, involving alpha-synuclein aggregation, inflammation, and mitochondrial dysfunction, requires a multifaceted therapeutic approach.\n Trial Design and Endpoints: The choice of clinical endpoints, duration of treatment, and patient selection criteria are crucial. The MDS-UPDRS, while a standard measure, may not be sensitive enough to detect subtle neuroprotective effects that do not immediately translate into overt symptomatic improvement.\n\nDespite the disappointing results from the Exenatide-PD3 trial, research into GLP-1RAs for PD is not being abandoned. The SPARK trial with semaglutide, along with other ongoing investigations, continues to explore this class of drugs. Scientists are now focusing on developing next-generation GLP-1RAs with improved brain penetrance and more targeted neuroprotective profiles. There is also a growing interest in combination therapies that address multiple pathological pathways in PD, where GLP-1RAs could potentially play a supportive role.\n\n## Conclusion\n\nThe journey to finding disease-modifying treatments for Parkinson's disease is fraught with challenges. While the initial promise of GLP-1RAs like semaglutide for dopaminergic neuroprotection was high, recent clinical data suggest that their direct impact on slowing disease progression in established PD may be limited. The SPARK trial's full results will provide further clarity on semaglutide's specific role. Future research will likely pivot towards earlier intervention, novel GLP-1RA formulations, and combination strategies to unlock the full neuroprotective potential of this intriguing class of compounds.\n\n## References\n\n[1] Kalinderi, K. GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease. PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11011817/\n[2] Lv, D. Neuroprotective effects of GLP-1 class drugs in Parkinson's disease. Frontiers in Neurology. 2024. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1462240/full\n[3] Foltynie, T., et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2025. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(